Development of drugs targeting the Cu-CTR1-LOX signaling axis may be a novel strategy to develop more efficient therapeutic approaches for pulmonary hypertension associated with hypoxia. This evidence concerns the gene SLC31A1 and pulmonary arterial hypertension.